Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0JQ2.L Stock Summary
In the News
0JQ2.L Financial details
Company Rating
-
Market Cap
20.36M
Income
-46.42M
Revenue
0
Book val./share
4.4
Cash/share
21.98
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
01 Mar 2024
P/E
-0.42
Forward P/E
-
PEG
0.05
P/S
-
P/B
1.72
P/C
0.34
P/FCF
-0.59
Quick Ratio
5.45
Current Ratio
5.62
Debt / Equity
3.02
LT Debt / Equity
3.02
-
-
EPS (TTM)
-22.73
EPS next Y
-
EPS next Q
-
EPS this Y
-72.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-21.79%
-
-
-
-
SMA20
-8.38%
SMA50
-53.45%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-76%
ROE
-261%
ROC
-0.77%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
2.69M
Shs Float
2.12M
-
-
-
-
Target Price
-
52W Range
5.27-23.7453
52W High
-67.96%
52W Low
+47.4%
RSI
49.05
Rel Volume
0.05
Avg Volume
257
Volume
14
Perf Week
15.88%
Perf Month
-20.92%
Perf Quarter
-
Perf Half Y
-53.35%
-
-
-
-
Beta
-1.51
-
-
Volatility
1.01%, 0.95%
Prev Close
-3.03%
Price
7.37
Change
-8.67%
0JQ2.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 8.88 | 6.07 | 8.54 | 2.56 | |
Net income per share | -124.73 | -137.89 | -99.59 | -108.32 | -29.48 | |
Operating cash flow per share | -101.15 | -135.52 | -86.58 | -82.21 | -51.9 | |
Free cash flow per share | -104.1 | -137.47 | -88.43 | -82.89 | -52.1 | |
Cash per share | 319.39 | 125.91 | 147.15 | 70.68 | 46.42 | |
Book value per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
Tangible book value per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
Share holders equity per share | 196.19 | 43.4 | 95.46 | 12.76 | 12.48 | |
Interest debt per share | 131.24 | 104.04 | 68.96 | 59.95 | 24.95 | |
Market cap | 115.84M | 364.33M | 360.36M | 79.12M | 28.37M | |
Enterprise value | -55.05M | 278.88M | 283.09M | -13.01M | -42.13M | |
P/E ratio | -1.74 | -3.86 | -3.45 | -0.55 | -0.63 | |
Price to sales ratio | 0 | 59.98 | 56.64 | 7.04 | 7.29 | |
POCF ratio | -2.14 | -3.93 | -3.97 | -0.73 | -0.36 | |
PFCF ratio | -2.08 | -3.87 | -3.89 | -0.73 | -0.36 | |
P/B Ratio | 1.1 | 12.27 | 3.6 | 4.71 | 1.5 | |
PTB ratio | 1.1 | 12.27 | 3.6 | 4.71 | 1.5 | |
EV to sales | 0 | 45.91 | 44.5 | -1.16 | -10.82 | |
Enterprise value over EBITDA | 0.86 | -3.19 | -2.99 | 0.12 | 0.52 | |
EV to operating cash flow | 1.02 | -3.01 | -3.12 | 0.12 | 0.53 | |
EV to free cash flow | 0.99 | -2.97 | -3.06 | 0.12 | 0.53 | |
Earnings yield | -0.58 | -0.26 | -0.29 | -1.8 | -1.58 | |
Free cash flow yield | -0.48 | -0.26 | -0.26 | -1.38 | -2.79 | |
Debt to equity | 0.67 | 2.4 | 0.72 | 4.7 | 2 | |
Debt to assets | 0.32 | 0.46 | 0.33 | 0.57 | 0.44 | |
Net debt to EBITDA | 2.65 | 0.98 | 0.81 | 0.85 | 0.87 | |
Current ratio | 10.41 | 4.26 | 7.71 | 3.32 | 3.35 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0.81 | 0.98 | 0.87 | 0.76 | 1.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 4.49 | 2.88 | 3.39 | 4.54 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0.01 | 0 | |
Capex to revenue | 0 | -0.22 | -0.31 | -0.08 | -0.08 | |
Capex to depreciation | -1.65 | -1.58 | -2.13 | -0.91 | -0.58 | |
Stock based compensation to revenue | 0 | 1.64 | 2.09 | 1.43 | 1.8 | |
Graham number | 742.01 | 366.94 | 462.49 | 176.38 | 90.98 | |
ROIC | -0.37 | -0.87 | -0.56 | -1.14 | -1.43 | |
Return on tangible assets | -0.3 | -0.61 | -0.47 | -1.02 | -0.52 | |
Graham Net | 106.45 | -40.17 | 40.43 | -10.44 | 1.89 | |
Working capital | 160.02M | 80.71M | 149.15M | 86.94M | 60.26M | |
Tangible asset value | 104.98M | 29.69M | 100M | 16.8M | 18.97M | |
Net current asset value | 61.04M | -19.15M | 49.77M | 1.74M | 18.1M | |
Invested capital | 0.67 | 2.4 | 0.72 | 4.7 | 2 | |
Average receivables | 1 | 5.78M | 10.58M | 12.47M | 7.77M | |
Average payables | 3.32M | 3.98M | 2.12M | 3.31M | 3.87M | |
Average inventory | 2.05M | 4.37M | 4.94M | 6.93M | 4.32M | |
Days sales outstanding | 0 | 694.85 | 551 | 498.3 | 18.29 | |
Days payables outstanding | 0 | 457.7 | 235.41 | 436.45 | 403.78 | |
Days of inventory on hand | 0 | 844.88 | 714.02 | 769.64 | 0 | |
Receivables turnover | 0 | 0.53 | 0.66 | 0.73 | 19.96 | |
Payables turnover | 0 | 0.8 | 1.55 | 0.84 | 0.9 | |
Inventory turnover | 0 | 0.43 | 0.51 | 0.47 | 2.56M | |
ROE | -0.64 | -3.18 | -1.04 | -8.49 | -2.36 | |
Capex per share | -2.95 | -1.95 | -1.85 | -0.67 | -0.21 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.28 | 0 | 0 | 0 | 0 | |
Net income per share | 19.25 | -7.97 | -6.99 | -4.36 | -3.41 | |
Operating cash flow per share | -10.37 | -8.53 | -4.68 | -3.18 | -1.16 | |
Free cash flow per share | -10.4 | -8.54 | -4.74 | -3.27 | -1.27 | |
Cash per share | 34.79 | 43.82 | 30.77 | 24.78 | 21.98 | |
Book value per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
Tangible book value per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
Share holders equity per share | -0.64 | 11.78 | 11.35 | 7.33 | 4.4 | |
Interest debt per share | 28.23 | 23.55 | 16.09 | 14.06 | 13.28 | |
Market cap | 17.03M | 30.05M | 30.35M | 34.38M | 22.54M | |
Enterprise value | -35.36M | -40.44M | -33.28M | -14.87M | -33.52M | |
P/E ratio | 0.15 | -0.58 | -0.52 | -0.83 | -0.65 | |
Price to sales ratio | 40.54 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.09 | -2.19 | -3.13 | -4.53 | -7.64 | |
PFCF ratio | -1.08 | -2.18 | -3.1 | -4.4 | -6.97 | |
P/B Ratio | -17.59 | 1.58 | 1.29 | 1.97 | 2.01 | |
PTB ratio | -17.59 | 1.58 | 1.29 | 1.97 | 2.01 | |
EV to sales | -84.2 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 2.46 | 4.46 | 3.33 | 1.62 | 3.21 | |
EV to operating cash flow | 2.26 | 2.94 | 3.44 | 1.96 | 11.35 | |
EV to free cash flow | 2.25 | 2.94 | 3.4 | 1.9 | 10.37 | |
Earnings yield | 1.71 | -0.43 | -0.48 | -0.3 | -0.39 | |
Free cash flow yield | -0.92 | -0.46 | -0.32 | -0.23 | -0.14 | |
Debt to equity | -44.05 | 2 | 1.42 | 1.92 | 3.02 | |
Debt to assets | 0.5 | 0.44 | 0.46 | 0.5 | 0.55 | |
Net debt to EBITDA | 3.64 | 7.77 | 6.37 | 5.38 | 5.38 | |
Current ratio | 2.1 | 3.35 | 6.95 | 6.65 | 5.62 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | -0.54 | 1.07 | 0.67 | 0.73 | 0.34 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 12.84 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.03 | 0.1 | |
Capex to revenue | -0.09 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.25 | -0.28 | -1.4 | -2.78 | -3.56 | |
Stock based compensation to revenue | 3.16 | 0 | 0 | 0 | 0 | |
Graham number | 16.66 | 45.97 | 42.24 | 26.81 | 18.38 | |
ROIC | -0.35 | -0.16 | -0.18 | -0.18 | -0.23 | |
Return on tangible assets | 0.34 | -0.15 | -0.2 | -0.16 | -0.14 | |
Graham Net | -22.5 | 1.78 | 7.23 | 4.3 | 2.45 | |
Working capital | 44.43M | 60.26M | 61.08M | 55.68M | 47.6M | |
Tangible asset value | -968K | 18.97M | 23.46M | 17.49M | 11.22M | |
Net current asset value | -1.99M | 18.1M | 22.58M | 16.53M | 8.01M | |
Invested capital | -44.05 | 2 | 1.42 | 1.92 | 3.02 | |
Average receivables | 7.01M | 192.5K | 155K | 116K | 117K | |
Average payables | 8.95M | 5.09M | 1.91M | 878.5K | 773.5K | |
Average inventory | 12.5K | 1 | 1 | 1 | 1 | |
Days sales outstanding | 40.71 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 60.12K | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0.01 | 0 | 0 | 0 | 0 | |
Receivables turnover | 2.21 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 11K | 0 | 0 | 0 | 0 | |
ROE | -30.03 | -0.68 | -0.62 | -0.6 | -0.78 | |
Capex per share | -0.03 | -0.01 | -0.05 | -0.09 | -0.11 |
0JQ2.L Frequently Asked Questions
What is Kala Pharmaceuticals, Inc. stock symbol ?
Kala Pharmaceuticals, Inc. is a US stock , located in Arlington of Ma and trading under the symbol 0JQ2.L
What is Kala Pharmaceuticals, Inc. stock quote today ?
Kala Pharmaceuticals, Inc. stock price is $7.37 today.
Is Kala Pharmaceuticals, Inc. stock public?
Yes, Kala Pharmaceuticals, Inc. is a publicly traded company.